Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ellen H,Nagami

第一单位： Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

作者： Ellen H,Nagami ^[1] ; Kinna,Thakarar ^[2] ; Paul E,Sax ^[3]

作者单位： Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA. ^[1] Division of Infectious Diseases, Maine Medical Center, Portland, Maine, USA.;Tufts University School of Medicine, Boston, Massachusetts, USA. ^[2] Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.;Harvard Medical School, Boston, Massachusetts, USA. ^[3]

关键词 HIV antiretroviral therapy dolutegravir drug resistance integrase strand transfer inhibitor

DOI 10.1093/ofid/ofab648

PMID 35111871

发布时间 2022-02-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Open forum infectious diseases

2022年9卷2期

ofab648页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance.

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance.

Open forum infectious diseases

相似文献

Open forum infectious diseases

相关期刊

检索历史清除